JP2023548858A5 - - Google Patents
Info
- Publication number
- JP2023548858A5 JP2023548858A5 JP2023526977A JP2023526977A JP2023548858A5 JP 2023548858 A5 JP2023548858 A5 JP 2023548858A5 JP 2023526977 A JP2023526977 A JP 2023526977A JP 2023526977 A JP2023526977 A JP 2023526977A JP 2023548858 A5 JP2023548858 A5 JP 2023548858A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- approximately
- seq
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110884P | 2020-11-06 | 2020-11-06 | |
| US63/110,884 | 2020-11-06 | ||
| US202163137972P | 2021-01-15 | 2021-01-15 | |
| US63/137,972 | 2021-01-15 | ||
| US202163173126P | 2021-04-09 | 2021-04-09 | |
| US63/173,126 | 2021-04-09 | ||
| US202163173919P | 2021-04-12 | 2021-04-12 | |
| US63/173,919 | 2021-04-12 | ||
| US202163174423P | 2021-04-13 | 2021-04-13 | |
| US63/174,423 | 2021-04-13 | ||
| US202163175440P | 2021-04-15 | 2021-04-15 | |
| US63/175,440 | 2021-04-15 | ||
| US202163219155P | 2021-07-07 | 2021-07-07 | |
| US202163203075P | 2021-07-07 | 2021-07-07 | |
| US202163203077P | 2021-07-07 | 2021-07-07 | |
| US63/203,077 | 2021-07-07 | ||
| US63/203,075 | 2021-07-07 | ||
| US63/219,155 | 2021-07-07 | ||
| PCT/US2021/058188 WO2022098955A1 (en) | 2020-11-06 | 2021-11-05 | Fcrn antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548858A JP2023548858A (ja) | 2023-11-21 |
| JP2023548858A5 true JP2023548858A5 (enExample) | 2024-11-14 |
Family
ID=81455198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526977A Pending JP2023548858A (ja) | 2020-11-06 | 2021-11-05 | Ｆｃｒｎ抗体及びその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220144946A1 (enExample) |
| EP (1) | EP4240417A4 (enExample) |
| JP (1) | JP2023548858A (enExample) |
| KR (1) | KR20230117575A (enExample) |
| AU (1) | AU2021376364A1 (enExample) |
| CA (1) | CA3200972A1 (enExample) |
| IL (1) | IL302516A (enExample) |
| JO (1) | JOP20230098A1 (enExample) |
| MX (1) | MX2023005313A (enExample) |
| PH (1) | PH12023551241A1 (enExample) |
| TW (1) | TW202233236A (enExample) |
| WO (1) | WO2022098955A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019001806A2 (pt) | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| MA51032A (fr) | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| BR112020011310A2 (pt) | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| JP7486437B2 (ja) | 2018-06-08 | 2024-05-17 | アルジェニクス ビーブイ | 免疫性血小板減少症を治療する組成物及び方法 |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| ES2992247T3 (es) | 2020-01-08 | 2024-12-11 | argenx BV | Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo |
| KR20250037789A (ko) | 2022-06-15 | 2025-03-18 | 아르젠엑스 비브이 | Fcrn/항원-결합 분자 및 사용 방법 |
| KR20250109193A (ko) * | 2022-11-07 | 2025-07-16 | 아르젠엑스 비브이 | Fcrn 길항제를 사용하여 루푸스 신염을 치료하는 방법 |
| EP4658368A1 (en) * | 2023-02-04 | 2025-12-10 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating hemolytic disease of the fetus and newborn |
| TW202527982A (zh) * | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025163617A1 (en) * | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) * | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
| WO2026083290A1 (en) * | 2024-10-16 | 2026-04-23 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6853178B2 (ja) * | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| WO2018063963A1 (en) * | 2016-09-28 | 2018-04-05 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| MA51032A (fr) * | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| BR112020011310A2 (pt) * | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| IL280280B2 (en) * | 2018-07-20 | 2024-11-01 | Momenta Pharmaceuticals Inc | Compositions of fcrn antibodies and methods of use thereof |
| JP7518821B2 (ja) * | 2018-10-16 | 2024-07-18 | ユーシービー バイオファルマ エスアールエル | 重症筋無力症の治療方法 |
| CA3148826A1 (en) * | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
-
2021
- 2021-11-05 CA CA3200972A patent/CA3200972A1/en active Pending
- 2021-11-05 WO PCT/US2021/058188 patent/WO2022098955A1/en not_active Ceased
- 2021-11-05 AU AU2021376364A patent/AU2021376364A1/en active Pending
- 2021-11-05 US US17/519,811 patent/US20220144946A1/en active Pending
- 2021-11-05 IL IL302516A patent/IL302516A/en unknown
- 2021-11-05 PH PH1/2023/551241A patent/PH12023551241A1/en unknown
- 2021-11-05 EP EP21890118.9A patent/EP4240417A4/en active Pending
- 2021-11-05 KR KR1020237018942A patent/KR20230117575A/ko active Pending
- 2021-11-05 TW TW110141386A patent/TW202233236A/zh unknown
- 2021-11-05 MX MX2023005313A patent/MX2023005313A/es unknown
- 2021-11-05 JP JP2023526977A patent/JP2023548858A/ja active Pending
-
2023
- 2023-05-04 JO JOJO/P/2023/0098A patent/JOP20230098A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103930444B (zh) | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 | |
| US20240417455A1 (en) | Treatment for rheumatoid arthritis | |
| US5741488A (en) | Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies | |
| JP2025172841A5 (enExample) | ||
| CA3118777A1 (en) | Methods of treating graves' ophthalmopathy using anti-fcrn antibodies | |
| JP2017160208A5 (enExample) | ||
| JP2021193121A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| US11248044B2 (en) | Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor | |
| JP2022515770A5 (enExample) | ||
| CN107922507A (zh) | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 | |
| WO1995009652A1 (en) | Treatment of autoimmune and inflammatory disorders | |
| JP2019512472A5 (enExample) | ||
| KR20250084991A (ko) | 항-FcRN 항체를 이용한 만성 염증성 탈수초성 다발성 신경병증의 치료 방법 | |
| WO2019020069A1 (zh) | 一种sost抗体药物组合物及其用途 | |
| JP2025514142A5 (enExample) | ||
| JP2024517087A5 (enExample) | ||
| CA3157797A1 (en) | Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies | |
| JP2024540435A5 (enExample) | ||
| JP6560808B2 (ja) | 抗（＋）メタンフェタミンモノクローナル抗体 | |
| US12139546B2 (en) | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling | |
| JP2024532438A5 (enExample) | ||
| JP2023531722A5 (enExample) | ||
| JP2022527542A5 (enExample) | ||
| WO2021018191A1 (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| JP2022502380A5 (enExample) |